JAGSNPHARM vs VENUSREM: Stock Comparison
VENUSREM is the larger company by market capitalisation. JAGSONPAL PHARMACEUTICALS shows a higher ROE, a higher dividend yield and a higher ROCE, while VENUSREM shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
JAGSNPHARM leads 5; VENUSREM leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | JAGSNPHARM | VENUSREM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | JAGSNPHARM | VENUSREM |
|---|---|---|
| Live Price | ₹232.89 | ₹1,797.5 |
| Day Change | -0.04% | 4.8% |
| Volume | 51,421 | 2.46 L |
| 52-Week High | ₹264.5 | ₹1,800.8 |
| 52-Week Low | ₹155 | ₹424 |
| Distance from 52W High | -11.95% | -0.18% |
Valuation
| Metric | JAGSNPHARM | VENUSREM |
|---|---|---|
| Market Cap | ₹1,537 Cr | ₹2,174 Cr |
| P/E Ratio | 34.02x | 18.62x |
| P/B Ratio | 5.64x | 3.26x |
| EPS | ₹2 | ₹17.18 |
| Book Value | ₹41.95 | ₹496.56 |
| Dividend Yield | 2.78% | 0.61% |
Growth
| Metric | JAGSNPHARM | VENUSREM |
|---|---|---|
| Revenue Growth (TTM YoY) | 9.6% | 33% |
| EPS Growth (TTM YoY) | 23.8% | 126.4% |
| Qtr Sales Growth | -71.37% | 0.03% |
| Qtr Profit Growth | -69.39% | -10.03% |
Profitability & Leverage
| Metric | JAGSNPHARM | VENUSREM |
|---|---|---|
| ROE | 15.6% | 14.4% |
| ROCE | 16.48% | 14.81% |
| Net Margin | 15% | 13.35% |
| Operating Margin | 20.38% | 17.12% |
| Debt to Equity | 0x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | JAGSNPHARM | VENUSREM |
|---|---|---|
| Promoter Holding | 25.55%▲ 0.43 pp | 41.76% |
| FII Holding | 2.3%▼ 0.14 pp | 2.92%▲ 0.12 pp |
| DII Holding | 0.62%▲ 0.4 pp | 0.89%▼ 0.31 pp |
| Public Holding | 28.03%▼ 1.42 pp | 54.43%▲ 0.19 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: JAGSONPAL PHARMACEUTICALS and VENUSREM.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.